NAMS MSCP MENOPAUSE CERTIFICATION EXAM
TEST BANK 2026 PRACTICE QUESTIONS WITH
VERIFIED ANSWERS & FULL RATIONALES
(MENOPAUSE SOCIETY CERTIFIED PRACTITIONER
STUDY GUIDE)
This premium question MSCP test bank is meticulously designed to mirror the
rigorous clinical standards of the 2026 Menopause Society Certified Practitioner
examination. Every multiple-choice question features verified answers alongside
detailed, bolded rationales that dissect advanced hormone therapy regimens,
non-hormonal alternatives, and bone health management guidelines. It serves
as an essential, high-yield study tool for healthcare professionals seeking
master-level certification in menopausal medicine and midlife women's health.
Question 1
A 52-year-old woman presents with severe vasomotor symptoms. She has a
history of deep vein thrombosis (DVT) following a lower extremity fracture four
years ago. She has an intact uterus. Which of the following is the most appropriate
management strategy?
A) Oral conjugated equine estrogens (CEE) combined with medroxyprogesterone
acetate (MPA)
B) Transdermal estradiol patch combined with oral micronized progesterone
C) Fezolinetant (Veozah) 45 mg orally once daily
D) Low-dose oral paroxetine 7.5 mg capsule at bedtime
,Answer: C
Rationale: A personal history of venous thromboembolism (VTE), including DVT,
is an absolute contraindication to both oral and transdermal systemic
menopausal hormone therapy (MHT) according to The Menopause Society
guidelines. Fezolinetant is a non-hormonal selective neurokinin-3 (NK3) receptor
antagonist specifically FDA-approved to treat moderate-to-severe vasomotor
symptoms by acting directly on the thermoregulatory center in the
hypothalamus, making it the safest, highly effective choice for this patient.
Paroxetine is also non-hormonal but is less effective than Fezolinetant for severe
symptoms and carries side effects like sexual dysfunction.
Question 2
A 55-year-old postmenopausal woman with an intact uterus is prescribed
continuous combined menopausal hormone therapy (MHT). Six months after
initiating therapy, she experiences persistent, irregular breakthrough bleeding.
Which of the following is the most appropriate next step in management?
A) Reassure her that breakthrough bleeding is normal for the first 12 months and
continue to monitor
B) Increase the dose of the progestogen component
C) Perform a transvaginal ultrasound or endometrial biopsy
D) Switch her to a cyclic MHT regimen
Answer: C
Rationale: While unscheduled breakthrough bleeding is common and often
benign during the first 4 to 6 months of a continuous combined MHT regimen,
persistent or new-onset irregular bleeding after 6 months mandates clinical
evaluation. A transvaginal ultrasound (TVUS) to evaluate endometrial thickness
or an endometrial biopsy must be performed to rule out endometrial hyperplasia
or malignancy.
Question 3
,A 34-year-old woman is diagnosed with spontaneous Premature Ovarian
Insufficiency (POI). She has no contraindications to hormone therapy. What is the
standard recommendation regarding the duration of her hormone replacement
therapy?
A) Limit therapy to 5 years to reduce the risk of invasive breast cancer
B) Continue therapy until at least the median age of natural menopause
(approximately age 51–52)
C) Stop therapy as soon as her vasomotor symptoms resolve
D) Discontinue therapy at age 40 to evaluate if her ovarian function has returned
Answer: B
Rationale: For women with Premature Ovarian Insufficiency (POI) or early
menopause, hormone therapy is recommended to continue until at least the
median age of natural menopause (51–52 years). This mitigates the long-term
risks of premature bone loss, cardiovascular disease, cognitive decline, and
urogenital atrophy associated with prolonged early estrogen deficiency. The
typical duration constraints applied to older postmenopausal women do not
apply here.
Question 4
Which of the following biomarkers is considered the most reliable indicator that a
woman has transitioned into the postmenopausal state?
A) Serum estradiol level < 20 pg/mL
B) Serum follicle-stimulating hormone (FSH) level > 30 IU/L on a single random
blood draw
C) 12 consecutive months of spontaneous amenorrhea without an alternative
pathological or physiological cause
D) Anti-Müllerian Hormone (AMH) levels below the assay's limit of detection
Answer: C
Rationale: Clinical diagnosis remains the gold standard for defining menopause.
It is defined retrospectively as 12 consecutive months of spontaneous
, amenorrhea following the loss of ovarian follicular activity. Serum hormone
levels like FSH and estradiol fluctuate wildly during the perimenopausal
transition, making a single random blood draw unreliable for diagnostic
verification.
Question 5
A 62-year-old postmenopausal woman with a T-score of -2.7 at the femoral neck
has been taking oral alendronate 70 mg weekly for 5 years. She has had no
fractures, and her bone mineral density (BMD) has remained stable. What is the
most appropriate next step in her bone health management?
A) Continue oral alendronate indefinitely without interruption
B) Transition immediately to denosumab (Prolia) injections every 6 months
C) Consider a "drug holiday" of 1 to 3 years with close monitoring of BMD
D) Switch to teriparatide (Forteo) sub-Q daily injections
Answer: C
Rationale: For postmenopausal women who have completed 5 years of oral
bisphosphonates (or 3 years of intravenous bisphosphonates) and are
determined to be at low-to-moderate risk of fracture (stable BMD, no prior
fractures), a "drug holiday" should be considered. Bisphosphonates accumulate
in bone tissue and provide continued residual antifracture efficacy after
cessation. This holiday minimizes the rare risks of atypical femur fractures (AFF)
and osteonecrosis of the jaw (ONJ).
Question 6
A 54-year-old breast cancer survivor taking Tamoxifen experiences severe,
disruptive night sweats. Which of the following non-hormonal medications is
strictly contraindicated for managing her vasomotor symptoms?
A) Venlafaxine (Effexor)
B) Gabapentin (Neurontin)
TEST BANK 2026 PRACTICE QUESTIONS WITH
VERIFIED ANSWERS & FULL RATIONALES
(MENOPAUSE SOCIETY CERTIFIED PRACTITIONER
STUDY GUIDE)
This premium question MSCP test bank is meticulously designed to mirror the
rigorous clinical standards of the 2026 Menopause Society Certified Practitioner
examination. Every multiple-choice question features verified answers alongside
detailed, bolded rationales that dissect advanced hormone therapy regimens,
non-hormonal alternatives, and bone health management guidelines. It serves
as an essential, high-yield study tool for healthcare professionals seeking
master-level certification in menopausal medicine and midlife women's health.
Question 1
A 52-year-old woman presents with severe vasomotor symptoms. She has a
history of deep vein thrombosis (DVT) following a lower extremity fracture four
years ago. She has an intact uterus. Which of the following is the most appropriate
management strategy?
A) Oral conjugated equine estrogens (CEE) combined with medroxyprogesterone
acetate (MPA)
B) Transdermal estradiol patch combined with oral micronized progesterone
C) Fezolinetant (Veozah) 45 mg orally once daily
D) Low-dose oral paroxetine 7.5 mg capsule at bedtime
,Answer: C
Rationale: A personal history of venous thromboembolism (VTE), including DVT,
is an absolute contraindication to both oral and transdermal systemic
menopausal hormone therapy (MHT) according to The Menopause Society
guidelines. Fezolinetant is a non-hormonal selective neurokinin-3 (NK3) receptor
antagonist specifically FDA-approved to treat moderate-to-severe vasomotor
symptoms by acting directly on the thermoregulatory center in the
hypothalamus, making it the safest, highly effective choice for this patient.
Paroxetine is also non-hormonal but is less effective than Fezolinetant for severe
symptoms and carries side effects like sexual dysfunction.
Question 2
A 55-year-old postmenopausal woman with an intact uterus is prescribed
continuous combined menopausal hormone therapy (MHT). Six months after
initiating therapy, she experiences persistent, irregular breakthrough bleeding.
Which of the following is the most appropriate next step in management?
A) Reassure her that breakthrough bleeding is normal for the first 12 months and
continue to monitor
B) Increase the dose of the progestogen component
C) Perform a transvaginal ultrasound or endometrial biopsy
D) Switch her to a cyclic MHT regimen
Answer: C
Rationale: While unscheduled breakthrough bleeding is common and often
benign during the first 4 to 6 months of a continuous combined MHT regimen,
persistent or new-onset irregular bleeding after 6 months mandates clinical
evaluation. A transvaginal ultrasound (TVUS) to evaluate endometrial thickness
or an endometrial biopsy must be performed to rule out endometrial hyperplasia
or malignancy.
Question 3
,A 34-year-old woman is diagnosed with spontaneous Premature Ovarian
Insufficiency (POI). She has no contraindications to hormone therapy. What is the
standard recommendation regarding the duration of her hormone replacement
therapy?
A) Limit therapy to 5 years to reduce the risk of invasive breast cancer
B) Continue therapy until at least the median age of natural menopause
(approximately age 51–52)
C) Stop therapy as soon as her vasomotor symptoms resolve
D) Discontinue therapy at age 40 to evaluate if her ovarian function has returned
Answer: B
Rationale: For women with Premature Ovarian Insufficiency (POI) or early
menopause, hormone therapy is recommended to continue until at least the
median age of natural menopause (51–52 years). This mitigates the long-term
risks of premature bone loss, cardiovascular disease, cognitive decline, and
urogenital atrophy associated with prolonged early estrogen deficiency. The
typical duration constraints applied to older postmenopausal women do not
apply here.
Question 4
Which of the following biomarkers is considered the most reliable indicator that a
woman has transitioned into the postmenopausal state?
A) Serum estradiol level < 20 pg/mL
B) Serum follicle-stimulating hormone (FSH) level > 30 IU/L on a single random
blood draw
C) 12 consecutive months of spontaneous amenorrhea without an alternative
pathological or physiological cause
D) Anti-Müllerian Hormone (AMH) levels below the assay's limit of detection
Answer: C
Rationale: Clinical diagnosis remains the gold standard for defining menopause.
It is defined retrospectively as 12 consecutive months of spontaneous
, amenorrhea following the loss of ovarian follicular activity. Serum hormone
levels like FSH and estradiol fluctuate wildly during the perimenopausal
transition, making a single random blood draw unreliable for diagnostic
verification.
Question 5
A 62-year-old postmenopausal woman with a T-score of -2.7 at the femoral neck
has been taking oral alendronate 70 mg weekly for 5 years. She has had no
fractures, and her bone mineral density (BMD) has remained stable. What is the
most appropriate next step in her bone health management?
A) Continue oral alendronate indefinitely without interruption
B) Transition immediately to denosumab (Prolia) injections every 6 months
C) Consider a "drug holiday" of 1 to 3 years with close monitoring of BMD
D) Switch to teriparatide (Forteo) sub-Q daily injections
Answer: C
Rationale: For postmenopausal women who have completed 5 years of oral
bisphosphonates (or 3 years of intravenous bisphosphonates) and are
determined to be at low-to-moderate risk of fracture (stable BMD, no prior
fractures), a "drug holiday" should be considered. Bisphosphonates accumulate
in bone tissue and provide continued residual antifracture efficacy after
cessation. This holiday minimizes the rare risks of atypical femur fractures (AFF)
and osteonecrosis of the jaw (ONJ).
Question 6
A 54-year-old breast cancer survivor taking Tamoxifen experiences severe,
disruptive night sweats. Which of the following non-hormonal medications is
strictly contraindicated for managing her vasomotor symptoms?
A) Venlafaxine (Effexor)
B) Gabapentin (Neurontin)
